Maprotiline

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: ~51 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: maprotiline · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Lowers seizure threshold; arrhythmia risk; serotonergic blunting unlikely.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: ~51 h (FDA label, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

1 listed · counted on reports

Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.

Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016., p. 97